Successful Acquisition of Turnstone Biologics
XOMA Royalty Corporation (NASDAQ: XOMA) has boldly taken a significant step forward in the realm of biotechnology acquisitions. Recently, the company finalized a tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ: TSBX). Stockholders of Turnstone received a cash payment of $0.34 per share along with a contingent value right, showcasing XOMA's commitment to enhancing its portfolio and fueling innovation within the biotech space.
Tender Offer Highlights
The tender offer was officially concluded on a Thursday, with a staggering total of 17,192,002 shares validly tendered. This represents about 74% of all outstanding shares of Turnstone, reflecting strong support for XOMA’s offer among Turnstone's stockholders. Such high participation signifies confidence in the strategic direction taken by XOMA. Following the expiration of the tender offer, XOMA went ahead to merge Turnstone with its subsidiary, XRA 3 Corp., transitioning Turnstone into a wholly owned subsidiary of XOMA Royalty.
Impacts of the Acquisition
With this acquisition, all shares of Turnstone that were not validly tendered will also receive the same cash offer. This move not only consolidates XOMA's presence in the biotech industry but also positions the company for significant growth as it now holds a more robust array of assets related to potential therapeutic candidates. Turnstone will cease trading on The Nasdaq Stock Market, aiming for a smooth delisting and deregistration process. This shift is anticipated to further streamline operations and align with XOMA's overarching goals of enhancing human health through innovative pharmaceutical solutions.
About XOMA Royalty Corporation
XOMA Royalty operates as a biotechnology royalty aggregator, specializing in acquiring future revenues linked to the development of therapeutic candidates. This strategic approach allows XOMA to provide non-dilutive funding to its partners, empowering them to advance their drug development efforts without the burden of traditional financing methods. As XOMA continues to grow its portfolio, the potential for collaboration and innovation within the life sciences sector expands tremendously.
Partnerships and Advisors
In this acquisition process, XOMA was supported by Gibson, Dunn & Crutcher LLP, while Leerink Partners played a critical role as the exclusive financial advisor. Legal counsel for Turnstone was provided by Cooley LLP, ensuring that all legal frameworks and guidelines were meticulously adhered to throughout the transaction.
Future Prospects
XOMA Royalty’s acquisition of Turnstone Biologics opens avenues for greater synergy, resource sharing, and innovation within its expanding portfolio. As XOMA continues to serve biotech companies advancing human health, stakeholders can anticipate enhanced operational efficiencies and new therapeutic solutions on the horizon. The integration of Turnstone signifies XOMA's strengths in recognizing valuable investment opportunities that promise significant returns in the evolving landscape of biotechnology.
Frequently Asked Questions
What was the cash offer per share for Turnstone stockholders?
The cash offer was $0.34 per share, along with a contingent value right.
What percentage of Turnstone's shares were tendered?
A total of approximately 74% of Turnstone's outstanding shares were tendered in the offer.
Who were the advisors involved in this acquisition?
XOMA Royalty was represented by Gibson, Dunn & Crutcher LLP, and Leerink Partners acted as the exclusive financial advisor.
What will happen to Turnstone's shares after the acquisition?
All shares that were not validly tendered will be converted into the right to receive the Offer Price following the acquisition.
How does XOMA Royalty support biotech companies?
XOMA provides non-dilutive funding by acquiring future revenue streams associated with therapeutic candidates, enabling companies to advance their drug development efforts.
